Financhill
Sell
48

OCGN Quote, Financials, Valuation and Earnings

Last price:
$0.52
Seasonality move :
-3.76%
Day range:
$0.55 - $0.58
52-week range:
$0.52 - $2.11
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
38.26x
P/B ratio:
5.64x
Volume:
2.4M
Avg. volume:
3.7M
1-year change:
-46.98%
Market cap:
$167.2M
Revenue:
$4.1M
EPS (TTM):
-$0.19

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
OCGN
Ocugen
$300K -$0.05 -100% -- $6.75
ADMA
ADMA Biologics
$112.8M $0.15 41.07% 75% $25.27
EDIT
Editas Medicine
$37.2M -$0.33 -23.05% -22.53% $3.75
EYPT
EyePoint Pharmaceuticals
$11M -$0.48 -24.38% -22.59% $33.00
INSM
Insmed
$102.4M -$1.16 19.4% -27.03% $95.54
TGTX
TG Therapeutics
$100.7M $0.20 84.44% -95.36% $42.83
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
OCGN
Ocugen
$0.57 $6.75 $167.2M -- $0.00 0% 38.26x
ADMA
ADMA Biologics
$18.67 $25.27 $4.4B 22.77x $0.00 0% 10.61x
EDIT
Editas Medicine
$1.41 $3.75 $117M -- $0.00 0% 3.59x
EYPT
EyePoint Pharmaceuticals
$6.63 $33.00 $455.7M -- $0.00 0% 8.63x
INSM
Insmed
$77.77 $95.54 $14.1B -- $0.00 0% 35.07x
TGTX
TG Therapeutics
$41.06 $42.83 $6.4B 293.29x $0.00 0% 19.55x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
OCGN
Ocugen
49.18% 4.395 12.22% 2.71x
ADMA
ADMA Biologics
17.17% 4.789 1.78% 2.76x
EDIT
Editas Medicine
-- 0.335 -- 3.71x
EYPT
EyePoint Pharmaceuticals
-- -2.597 -- 7.57x
INSM
Insmed
79.45% 6.110 8.91% 4.99x
TGTX
TG Therapeutics
52.36% 3.612 5.21% 4.85x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
OCGN
Ocugen
-- -$13.8M -136.46% -171.04% -1811.52% -$10.4M
ADMA
ADMA Biologics
$63.3M $38.3M 60.85% 93.41% 31.98% $23.9M
EDIT
Editas Medicine
-- -$34.4M -100% -100% -112.28% -$51.3M
EYPT
EyePoint Pharmaceuticals
$10.8M -$45.2M -50.34% -50.34% -356.36% -$36.2M
INSM
Insmed
$78.3M -$245.2M -82.19% -41989.34% -205.36% -$202.8M
TGTX
TG Therapeutics
$92.8M $29.9M 6.86% 12.81% 30.05% -$25.7M

Ocugen vs. Competitors

  • Which has Higher Returns OCGN or ADMA?

    ADMA Biologics has a net margin of -1816.75% compared to Ocugen's net margin of 95.19%. Ocugen's return on equity of -171.04% beat ADMA Biologics's return on equity of 93.41%.

    Company Gross Margin Earnings Per Share Invested Capital
    OCGN
    Ocugen
    -- -$0.05 $58.3M
    ADMA
    ADMA Biologics
    53.88% $0.46 $421.4M
  • What do Analysts Say About OCGN or ADMA?

    Ocugen has a consensus price target of $6.75, signalling upside risk potential of 1078.83%. On the other hand ADMA Biologics has an analysts' consensus of $25.27 which suggests that it could grow by 35.36%. Given that Ocugen has higher upside potential than ADMA Biologics, analysts believe Ocugen is more attractive than ADMA Biologics.

    Company Buy Ratings Hold Ratings Sell Ratings
    OCGN
    Ocugen
    2 0 0
    ADMA
    ADMA Biologics
    4 0 0
  • Is OCGN or ADMA More Risky?

    Ocugen has a beta of 3.883, which suggesting that the stock is 288.285% more volatile than S&P 500. In comparison ADMA Biologics has a beta of 0.605, suggesting its less volatile than the S&P 500 by 39.509%.

  • Which is a Better Dividend Stock OCGN or ADMA?

    Ocugen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocugen pays -- of its earnings as a dividend. ADMA Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios OCGN or ADMA?

    Ocugen quarterly revenues are $764K, which are smaller than ADMA Biologics quarterly revenues of $117.5M. Ocugen's net income of -$13.9M is lower than ADMA Biologics's net income of $111.9M. Notably, Ocugen's price-to-earnings ratio is -- while ADMA Biologics's PE ratio is 22.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocugen is 38.26x versus 10.61x for ADMA Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OCGN
    Ocugen
    38.26x -- $764K -$13.9M
    ADMA
    ADMA Biologics
    10.61x 22.77x $117.5M $111.9M
  • Which has Higher Returns OCGN or EDIT?

    Editas Medicine has a net margin of -1816.75% compared to Ocugen's net margin of -148.33%. Ocugen's return on equity of -171.04% beat Editas Medicine's return on equity of -100%.

    Company Gross Margin Earnings Per Share Invested Capital
    OCGN
    Ocugen
    -- -$0.05 $58.3M
    EDIT
    Editas Medicine
    -- -$0.55 $134.3M
  • What do Analysts Say About OCGN or EDIT?

    Ocugen has a consensus price target of $6.75, signalling upside risk potential of 1078.83%. On the other hand Editas Medicine has an analysts' consensus of $3.75 which suggests that it could grow by 165.96%. Given that Ocugen has higher upside potential than Editas Medicine, analysts believe Ocugen is more attractive than Editas Medicine.

    Company Buy Ratings Hold Ratings Sell Ratings
    OCGN
    Ocugen
    2 0 0
    EDIT
    Editas Medicine
    4 9 0
  • Is OCGN or EDIT More Risky?

    Ocugen has a beta of 3.883, which suggesting that the stock is 288.285% more volatile than S&P 500. In comparison Editas Medicine has a beta of 1.876, suggesting its more volatile than the S&P 500 by 87.581%.

  • Which is a Better Dividend Stock OCGN or EDIT?

    Ocugen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Editas Medicine offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocugen pays -- of its earnings as a dividend. Editas Medicine pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios OCGN or EDIT?

    Ocugen quarterly revenues are $764K, which are smaller than Editas Medicine quarterly revenues of $30.6M. Ocugen's net income of -$13.9M is higher than Editas Medicine's net income of -$45.4M. Notably, Ocugen's price-to-earnings ratio is -- while Editas Medicine's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocugen is 38.26x versus 3.59x for Editas Medicine. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OCGN
    Ocugen
    38.26x -- $764K -$13.9M
    EDIT
    Editas Medicine
    3.59x -- $30.6M -$45.4M
  • Which has Higher Returns OCGN or EYPT?

    EyePoint Pharmaceuticals has a net margin of -1816.75% compared to Ocugen's net margin of -357.26%. Ocugen's return on equity of -171.04% beat EyePoint Pharmaceuticals's return on equity of -50.34%.

    Company Gross Margin Earnings Per Share Invested Capital
    OCGN
    Ocugen
    -- -$0.05 $58.3M
    EYPT
    EyePoint Pharmaceuticals
    92.96% -$0.64 $336.5M
  • What do Analysts Say About OCGN or EYPT?

    Ocugen has a consensus price target of $6.75, signalling upside risk potential of 1078.83%. On the other hand EyePoint Pharmaceuticals has an analysts' consensus of $33.00 which suggests that it could grow by 397.74%. Given that Ocugen has higher upside potential than EyePoint Pharmaceuticals, analysts believe Ocugen is more attractive than EyePoint Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    OCGN
    Ocugen
    2 0 0
    EYPT
    EyePoint Pharmaceuticals
    9 0 0
  • Is OCGN or EYPT More Risky?

    Ocugen has a beta of 3.883, which suggesting that the stock is 288.285% more volatile than S&P 500. In comparison EyePoint Pharmaceuticals has a beta of 1.409, suggesting its more volatile than the S&P 500 by 40.932%.

  • Which is a Better Dividend Stock OCGN or EYPT?

    Ocugen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EyePoint Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocugen pays -- of its earnings as a dividend. EyePoint Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios OCGN or EYPT?

    Ocugen quarterly revenues are $764K, which are smaller than EyePoint Pharmaceuticals quarterly revenues of $11.6M. Ocugen's net income of -$13.9M is higher than EyePoint Pharmaceuticals's net income of -$41.4M. Notably, Ocugen's price-to-earnings ratio is -- while EyePoint Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocugen is 38.26x versus 8.63x for EyePoint Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OCGN
    Ocugen
    38.26x -- $764K -$13.9M
    EYPT
    EyePoint Pharmaceuticals
    8.63x -- $11.6M -$41.4M
  • Which has Higher Returns OCGN or INSM?

    Insmed has a net margin of -1816.75% compared to Ocugen's net margin of -225.53%. Ocugen's return on equity of -171.04% beat Insmed's return on equity of -41989.34%.

    Company Gross Margin Earnings Per Share Invested Capital
    OCGN
    Ocugen
    -- -$0.05 $58.3M
    INSM
    Insmed
    74.96% -$1.32 $1.4B
  • What do Analysts Say About OCGN or INSM?

    Ocugen has a consensus price target of $6.75, signalling upside risk potential of 1078.83%. On the other hand Insmed has an analysts' consensus of $95.54 which suggests that it could grow by 22.86%. Given that Ocugen has higher upside potential than Insmed, analysts believe Ocugen is more attractive than Insmed.

    Company Buy Ratings Hold Ratings Sell Ratings
    OCGN
    Ocugen
    2 0 0
    INSM
    Insmed
    12 0 0
  • Is OCGN or INSM More Risky?

    Ocugen has a beta of 3.883, which suggesting that the stock is 288.285% more volatile than S&P 500. In comparison Insmed has a beta of 1.280, suggesting its more volatile than the S&P 500 by 27.99%.

  • Which is a Better Dividend Stock OCGN or INSM?

    Ocugen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocugen pays -- of its earnings as a dividend. Insmed pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios OCGN or INSM?

    Ocugen quarterly revenues are $764K, which are smaller than Insmed quarterly revenues of $104.4M. Ocugen's net income of -$13.9M is higher than Insmed's net income of -$235.5M. Notably, Ocugen's price-to-earnings ratio is -- while Insmed's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocugen is 38.26x versus 35.07x for Insmed. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OCGN
    Ocugen
    38.26x -- $764K -$13.9M
    INSM
    Insmed
    35.07x -- $104.4M -$235.5M
  • Which has Higher Returns OCGN or TGTX?

    TG Therapeutics has a net margin of -1816.75% compared to Ocugen's net margin of 21.57%. Ocugen's return on equity of -171.04% beat TG Therapeutics's return on equity of 12.81%.

    Company Gross Margin Earnings Per Share Invested Capital
    OCGN
    Ocugen
    -- -$0.05 $58.3M
    TGTX
    TG Therapeutics
    85.77% $0.15 $466.8M
  • What do Analysts Say About OCGN or TGTX?

    Ocugen has a consensus price target of $6.75, signalling upside risk potential of 1078.83%. On the other hand TG Therapeutics has an analysts' consensus of $42.83 which suggests that it could grow by 4.32%. Given that Ocugen has higher upside potential than TG Therapeutics, analysts believe Ocugen is more attractive than TG Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    OCGN
    Ocugen
    2 0 0
    TGTX
    TG Therapeutics
    5 0 0
  • Is OCGN or TGTX More Risky?

    Ocugen has a beta of 3.883, which suggesting that the stock is 288.285% more volatile than S&P 500. In comparison TG Therapeutics has a beta of 2.303, suggesting its more volatile than the S&P 500 by 130.31%.

  • Which is a Better Dividend Stock OCGN or TGTX?

    Ocugen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocugen pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios OCGN or TGTX?

    Ocugen quarterly revenues are $764K, which are smaller than TG Therapeutics quarterly revenues of $108.2M. Ocugen's net income of -$13.9M is lower than TG Therapeutics's net income of $23.3M. Notably, Ocugen's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 293.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocugen is 38.26x versus 19.55x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OCGN
    Ocugen
    38.26x -- $764K -$13.9M
    TGTX
    TG Therapeutics
    19.55x 293.29x $108.2M $23.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is CyberArk The Next Big Cybersecurity Stock?
Is CyberArk The Next Big Cybersecurity Stock?

CyberArk Software (NASDAQ: CYBR) recently reported phenomenal quarter numbers, passing…

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

2 Dividend Stocks to Buy in a Recession
2 Dividend Stocks to Buy in a Recession

While many economists and investors initially expected 2025 to be…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
52
RGC alert for Mar 18

Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.

Buy
63
EXOD alert for Mar 18

Exodus Movement [EXOD] is down 3.96% over the past day.

Sell
45
MNPR alert for Mar 18

Monopar Therapeutics [MNPR] is up 0.93% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock